Final Logo-01.png
Remicade Biosimilars Market Size & Share to Exceed USD 34.4 Billion by 2034, at CAGR of 9.30% - By PMI
08. Februar 2024 17:30 ET | PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of...
Final Logo-01.png
Monoclonal Antibody Diagnostic Reagents Market Size & Share to Exceed USD 27.2 Billion by 2034, at CAGR of 12.30% – By PMI
08. Februar 2024 15:30 ET | PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Monoclonal Antibody Diagnostic Reagents Market size was valued at about USD 8.5 Billion in 2024 and expected to...
Pharmacokinetics of Ustekinumab (CT-P43) Oral (RT-111) vs SC Injection
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
05. Februar 2024 08:00 ET | Rani Therapeutics, LLC
- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111...
Rani-Logo.jpg
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
05. Juni 2023 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
16. März 2023 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...